Proto-Oncogene Proteins c-met

"Proto-Oncogene Proteins c-met" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cell surface protein-tyrosine kinase receptors for HEPATOCYTE GROWTH FACTOR. They consist of an extracellular alpha chain which is disulfide-linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and sites critical for the regulation of kinase activity. Mutations in the c-met proto-oncogene are associated with papillary renal carcinoma and other neoplasia.

Descriptor ID	D019859
MeSH Number(s)	D08.811.913.696.620.682.725.400.075 D12.776.543.750.630.186 D12.776.543.750.750.400.100 D12.776.624.664.700.186
Concept/Terms	Proto-Oncogene Proteins c-met Proto-Oncogene Proteins c-met Proto Oncogene Proteins c met MET Receptor Tyrosine Kinase c-Met Receptor Tyrosine Kinase c Met Receptor Tyrosine Kinase Receptor, Hepatocyte Growth Factor met Proto-Oncogene Proteins Proto-Oncogene Proteins, met met Proto Oncogene Proteins Scatter Factor Receptor Receptor, HGF HGF Receptor Hepatocyte Growth Factor Receptor c-met Proteins c met Proteins MET Proto-Oncogene, Receptor Tyrosine Kinase MET Proto Oncogene, Receptor Tyrosine Kinase Receptor, Scatter Factor

Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-met".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
Proto-Oncogene Proteins c-met [D08.811.913.696.620.682.725.400.075]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
Proto-Oncogene Proteins c-met [D12.776.543.750.630.186]
Receptors, Peptide [D12.776.543.750.750]
Receptors, Growth Factor [D12.776.543.750.750.400]
Proto-Oncogene Proteins c-met [D12.776.543.750.750.400.100]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]
Proto-Oncogene Proteins c-met [D12.776.624.664.700.186]

Below are MeSH descriptors whose meaning is related to "Proto-Oncogene Proteins c-met".

Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-met".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Proto-Oncogene Proteins c-met" by people in this website by year, and whether "Proto-Oncogene Proteins c-met" was a major or minor topic of these publications.

Bar chart showing 6 publications over 5 distinct years, with a maximum of 2 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	1	1
2013	1	0	1
2014	1	1	2
2015	1	0	1
2016	1	0	1

Below are the most recent publications written about "Proto-Oncogene Proteins c-met" by people in Profiles.

Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M, Montironi R, Massari F. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? Int J Mol Sci. 2021 Jun 09; 22(12).

View in: PubMed
Modena A, Massari F, Ciccarese C, Brunelli M, Santoni M, Montironi R, Martignoni G, Tortora G. Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? Target Oncol. 2016 08; 11(4):431-46.

View in: PubMed
Ciccarese C, Brunelli M, Montironi R, Fiorentino M, Iacovelli R, Heng D, Tortora G, Massari F. The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev. 2016 Sep; 49:37-44.

View in: PubMed
Veenstra C, P?rez-Tenorio G, Stelling A, Karlsson E, Mirwani SM, Nordensk?ljd B, Fornander T, St?l O. Met and its ligand HGF are associated with clinical outcome in breast cancer. Oncotarget. 2016 Jun 14; 7(24):37145-37159.

View in: PubMed
Smith BD, Kaufman MD, Leary CB, Turner BA, Wise SC, Ahn YM, Booth RJ, Caldwell TM, Ensinger CL, Hood MM, Lu WP, Patt TW, Patt WC, Rutkoski TJ, Samarakoon T, Telikepalli H, Vogeti L, Vogeti S, Yates KM, Chun L, Stewart LJ, Clare M, Flynn DL. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2. Mol Cancer Ther. 2015 Sep; 14(9):2023-34.

View in: PubMed
Whitsett TG, Fortin Ensign SP, Dhruv HD, Inge LJ, Kurywchak P, Wolf KK, LoBello J, Kingsley CB, Allen JW, Weiss GJ, Tran NL. FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion. Clin Exp Metastasis. 2014 Aug; 31(6):613-23.

View in: PubMed
Davison JM, Yee M, Krill-Burger JM, Lyons-Weiler MA, Kelly LA, Sciulli CM, Nason KS, Luketich JD, Michalopoulos GK, LaFramboise WA. The degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma. PLoS One. 2014; 9(1):e79079.

View in: PubMed
Kwon Y, Smith BD, Zhou Y, Kaufman MD, Godwin AK. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene. 2015 Jan 08; 34(2):144-53.

View in: PubMed
Demirci C, Ernst S, Alvarez-Perez JC, Rosa T, Valle S, Shridhar V, Casinelli GP, Alonso LC, Vasavada RC, Garc?a-Ocana A. Loss of HGF/c-Met signaling in pancreatic ?-cells leads to incomplete maternal ?-cell adaptation and gestational diabetes mellitus. Diabetes. 2012 May; 61(5):1143-52.

View in: PubMed
Mellado-Gil J, Rosa TC, Demirci C, Gonzalez-Pertusa JA, Velazquez-Garcia S, Ernst S, Valle S, Vasavada RC, Stewart AF, Alonso LC, Garcia-Oca?a A. Disruption of hepatocyte growth factor/c-Met signaling enhances pancreatic beta-cell death and accelerates the onset of diabetes. Diabetes. 2011 Feb; 60(2):525-36.

View in: PubMed

People

Explore

Similar Concepts

Top Journals